Strata Skin Sciences

THE SKIN OF COLOR SOCIETY (SOCS) REPORTS A BANNER YEAR OF PROGRESS TOWARD GREATER DIVERSITY & INCLUSION IN DERMATOLOGY AND HEALTH EQUITY FOR PATIENTS OF COLOR

Retrieved on: 
Wednesday, December 27, 2023
SOCS, Master of Science, Inflammation, Congress, Health, National Medical Association, MPH, Symposium, Travel, Howard University, Procter & Gamble, Collection, Resident, Marriott Marquis, Eli Lilly, MBA, Challenge, Health equity, Strata Skin Sciences, Avita Medical, Physician, DF, WCD, UCB, La Roche-Posay, DEI, Patient, Medicine, L'Oréal, FAAD, Hair loss, DRS, Patient safety, Education, International League, Google Health, Inclusion, Volunteering, Summit, Bristol Myers Squibb, AbbVie, Pharmaceutical industry

Several signature SOCS programs and newer initiatives that took place this year made uniquely important contributions to the field, as follows.

Key Points: 
  • Several signature SOCS programs and newer initiatives that took place this year made uniquely important contributions to the field, as follows.
  • Right" and much more, this enlightening collection addresses many issues of importance to patients of color and the physicians who care for them.
  • 8 Travel Grants to the SOCS Meeting the Challenge Summit awarded to Dermatology Residents, supported by Summit sponsorships.
  • 48 SOCS Mentor-Mentee pairings in the SOCS Mentorship program were facilitated, thanks to individual donations made to the SOCS Foundation.

STRATA Skin Sciences Reports Third Quarter 2023 Revenue

Retrieved on: 
Tuesday, November 14, 2023
Webcast, EBITDA, ID, Three Months, SSKN, Strata Skin Sciences, International, Depreciation, Laser, Marketing, Advertising, Financial Accounting Standards Board, GAAP, Partnership, Growth, Dermatology, Toys "R" Us Canada, STRATA, Video game, Cryptocurrency, Bank

Third Quarter 2023 and Recent Business Highlights:

Key Points: 
  • Third Quarter 2023 and Recent Business Highlights:
    Total Revenues were $8.9 million compared to $9.4 million for the third quarter of 2022, a total decrease of 6.0%.
  • “I am pleased to have rejoined the STRATA Skin Sciences team,” commented Dr. Dolev Rafaeli, Vice-Chairman, and Chief Executive Officer.
  • Global recurring revenues for the third quarter of 2023 were $5.3 million, compared to global recurring revenues of $5.8 million for the third quarter of 2022.
  • Other expense for the third quarter of 2023 was $0.4 million, compared to $0.2 million for the third quarter of 2022.

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, Surgery, General Health, Health, Medical Devices, Health Technology, Technology, Other Technology, CFO, Plasma, Cardiac electrophysiology, Accounting, Strata Skin Sciences, Lehigh University, Senior, Marketing, Financial management, Forecasting, Cantel Medical Corporation, Growth, PDSB, EP, Pharmaceutical industry, Nursing, Science

Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023.

Key Points: 
  • Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023.
  • Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023.
  • “Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies,” said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical.
  • “I am pleased to join the Company at this exciting time, and look forward to working with Charlie and the rest of the team as we lead Apyx Medical through its next stage of growth and development.”
    Mr. Hill joins Apyx Medical from PDS Biotechnology Corporation (Nasdaq: PDSB; “PDS Biotech”), a clinical-stage immunotherapy company, where he served as Chief Financial Officer, leading all aspects of the company’s budgeting, forecasting, financial management and reporting.

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, August 15, 2023
GMP, Data management, Operating cost, Chairperson, Table, VLU, Event, Conference call, Bank statement, Eastern Time Zone, Bromelain (pharmacology), Tax, European Directive on Traditional Herbal Medicinal Products, BCC Lions F.C., Strata Skin Sciences, Research, HERE, Trial of the century, Forecasting, EMA, Committee, European Medicines Agency, Taro Pharmaceuticals, EBITDA, Patient, Sun Pharma, NEXT, Depreciation, Mouth ulcer, Growth, Committee for Medicinal Products for Human Use, Phase, FDA, Carcinoma, Regulation of tobacco by the U.S. Food and Drug Administration, BARDA, BCC, Adjustment, Food, Conference, CHMP, Pharmaceutical industry, Rare-earth element, Medical device, Video game, Bookkeeping, Insurance, Vericel

YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Key Points: 
  • Second Quarter 2023 Highlights and Recent Developments:
    Shipped NexoBrid finished product to Vericel for the U.S. commercial launch in June 2023.
  • Revenues: Revenues for the second quarter 2023 were $4.8 million, compared to $4.7 million in the second quarter of 2022.
  • Research and development expenses in the second quarter 2023 were $2.0 million compared to $2.2 million in the second quarter of 2022.
  • Operating Results: Operating loss in the second quarter of 2023 was $4.0 million, compared to a $3.7 million loss in the second quarter of 2022.

Alcami Announces CEO Transition

Retrieved on: 
Monday, June 5, 2023
Pepperdine University, Partner, The Crane Group Companies, MBA, Strata Skin Sciences, Bucknell University, Organization, CDMO, Retirement, Entrepreneurship, Growth, SKNV, Management, Stiefel

Bill Humphries to succeed Patrick Walsh as CEO effective June 5th, 2023

Key Points: 
  • Bill Humphries to succeed Patrick Walsh as CEO effective June 5th, 2023
    WILMINGTON, N.C., June 5, 2023 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the retirement of Patrick Walsh and the subsequent appointment of Bill Humphries as the next CEO, effective June 5th, 2023.
  • Prior to Alcami, Humphries' executive leadership roles included CEO at Isosceles Pharmaceuticals, President and Group Company Chairman of Ortho-Dermatologics, CEO of Merz North America, President of Stiefel, a GSK Company and Vice President of US Skincare at Allergan Pharmaceuticals.
  • He further commented, "I feel fortunate that Pat is remaining in the Alcami family, and the opportunity to work with the Alcami team, Pat, our outstanding Board members and Partners provides me every confidence in the future growth of Alcami."
  • With this transition, we are delighted to welcome Bill Humphries as our new CEO.

STRATA Skin Sciences Enters India Market with Exclusive Distribution Agreement with Spectra Medical

Retrieved on: 
Monday, May 15, 2023
Strata Skin Sciences, Partnership, Prevalence, Marketing, STRATA, Acne, Psoriasis, Light, SSKN, Dermatology, Laser, Vitiligo, Pharmaceutical industry, HORSHAM

HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it has entered into an exclusive, three-year agreement with Spectra Medical India Pvt Ltd., a distribution company representing medical laser and aesthetic equipment manufacturers, for the distribution of TheraClear®X, VTRAC®, and XTRAC® in India.

Key Points: 
  • India has the highest prevalence of vitiligo in the world, at about 8.8%1
    HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it has entered into an exclusive, three-year agreement with Spectra Medical India Pvt Ltd., a distribution company representing medical laser and aesthetic equipment manufacturers, for the distribution of TheraClear®X, VTRAC®, and XTRAC® in India.
  • “We are excited to expand into the acne, psoriasis, and vitiligo market in India with Spectra Medical,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.
  • “Led by Ramamoorthy Sundaram, Spectra Medical has over 20 years of experience in the medical distribution industry, and is India’s leading distributor of dermatology medical devices.
  • India presents STRATA with a unique opportunity as there are no excimer laser solutions for phototherapy treatments currently available today.

STRATA Skin Sciences Announces the Launch of New, Patient-Focused XTRAC® Website

Retrieved on: 
Thursday, March 2, 2023
SSKN, Dermatitis, Strata Skin Sciences, Marketing, Atopic dermatitis, Laser, Patient, Vitiligo, Psoriasis, Pharmaceutical industry

HORSHAM, Pa., March 02, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the launch of the new XTRAC® website, www.xtracclear.com .

Key Points: 
  • HORSHAM, Pa., March 02, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the launch of the new XTRAC® website, www.xtracclear.com .
  • The new website educates patients on XTRAC excimer laser therapy for the treatment of psoriasis, vitiligo, and atopic dermatitis (eczema).
  • Additional features of the site include:
    “We are proud to announce the launch of our new XTRAC website,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.
  • “Our goal in designing this new resource is to increase product awareness, make it easy for patients to seek out treatment at their convenience, and ultimately allow more patients with these conditions to benefit from XTRAC therapy.”

STRATA Skin Sciences Expects Record Full Year 2022 Revenue

Retrieved on: 
Wednesday, February 1, 2023
Marketing, Strata Skin Sciences, Growth, STRATA, Pharmaceutical industry

HORSHAM, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced record, preliminary revenue for the full year 2022 in the range of $35-$36 million, which is at the upper-end of previously announced guidance ($33-$35 million) and compares to $30 million reported for the full year 2021.

Key Points: 
  • HORSHAM, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced record, preliminary revenue for the full year 2022 in the range of $35-$36 million, which is at the upper-end of previously announced guidance ($33-$35 million) and compares to $30 million reported for the full year 2021.
  • “Last year proved to be a record year for STRATA with preliminary full year revenue in the range of $35-$36 million, representing approximately 17-19% growth over the full year 2021,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.
  • “This past year the team remained focused on growing the top-line through driving XTRAC® usage, refurbishing and redeploying underutilized devices, and focusing on international sales.
  • We are excited by these positive results and look forward to continuing this momentum throughout 2023.”
    The preliminary, unaudited results described in this press release are estimates and are subject to revision until the company reports its full financial results for the year ended December 2022, which is anticipated in March 2023.

STRATA Skin Sciences Announces Poster Accepted at ODAC Dermatology, Aesthetic & Surgical Conference

Retrieved on: 
Friday, January 13, 2023
Moderate, Acne, Face, MHS, Lake, Safety, MD, PPT, Strata Skin Sciences, Conference, Marketing, Comedo, DRS, Red, Male, Pigment, Aesthetics, Female, Skin, Pharmaceutical industry, Medical imaging, Cosmetics, Dermatology, Patient

The objective of the clinical assessments was to evaluate, via photographs, changes in visible acne lesions and skin texture after a series of tailored photopneumatic therapy (PPT) treatments delivered to patients with mild-moderate acne.

Key Points: 
  • The objective of the clinical assessments was to evaluate, via photographs, changes in visible acne lesions and skin texture after a series of tailored photopneumatic therapy (PPT) treatments delivered to patients with mild-moderate acne.
  • Patients were eligible to receive 4-6 in office photopneumatic treatments 1-2 weeks apart for 15 minutes per treatment.
  • The duration of the treatments were tailored to each patient’s skin type, severity of acne and type of acne lesions.
  • Munavalli, Smith and Smith for their contributions,” stated Bob Moccia, President and Chief Executive Officer of STRATA Skin Sciences.

STRATA Skin Sciences Expands into $300 Million Market with Exclusive Distribution Agreement in Mexico

Retrieved on: 
Monday, January 9, 2023
Vitiligo, Acne, STRATA, Skin, Psoriasis, Partnership, Strata Skin Sciences, Marketing, Acquisition, Pharmaceutical industry

“We are excited to have entered into an exclusive sales agreement with MINO Labs,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.

Key Points: 
  • “We are excited to have entered into an exclusive sales agreement with MINO Labs,” stated Bob Moccia, Chief Executive Officer of STRATA Skin Sciences.
  • “With the addition of Mexico, STRATA has the potential to access a nearly $300 million market for acne, psoriasis, and vitiligo.
  • MINO’s 20 years of experience in the pharmaceutical industry and deep expertise in the Central and Latin American region, will allow STRATA to provide those in Mexico who suffer from skin conditions another treatment option.
  • In particular, there is a high need for acne treatments as 80%1 of the Mexican population is affected by low to severe acne.